Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)

NCT02308228
Conditions
Aging
Interventions
Progressive Resistance Training, Metformin
Behavioral · Drug
Lead sponsor
Philip Kern
Other
Eligibility
65 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Lexington, Kentucky
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

RELIANCE: Moringa in Lactation and Early Childhood

NCT07605091
Conditions
Breast Feeding, Lactation
Interventions
Moringa Leaf Powder, Carrier
Dietary Supplement · Other
Lead sponsor
Philip Kern
Other
Eligibility
7 Days to 99 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brooklyn, New York
Completed Early Phase 1 Interventional

Brown Fat Activation Study

NCT02919176
Conditions
Obese, Metabolic Syndrome
Interventions
Mirabegron, Pioglitazone, Mirabegron and Pioglitazone
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Pre-diabetes, Obesity
Interventions
Mirabegron 50 MG, Tadalafil 10 MG, Placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Fish Oils on Inflammation and Insulin Resistance

NCT00579436
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
omega-3 fatty acid, placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cold Induced Changes in White Adipose

NCT02596776
Conditions
Obese, Normal Body Weight, Prediabetes, Metabolic Syndrome
Interventions
Fat biopsy, Propranolol and fat biopsy, heavy water and fat biopsy
Procedure · Drug · Other
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanisms Underlying Metabolic Syndrome in Obesity

NCT00579813
Conditions
Metabolic Syndrome, Insulin Resistance, Prediabetes
Interventions
Pioglitazone
Drug
Lead sponsor
Philip Kern
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Little Rock, Arkansas • Lexington, Kentucky
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mechanisms for Activation of Beige Adipose Tissue in Humans

NCT04666636
Conditions
PreDiabetes
Interventions
Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 2 Interventional Results available

Blood Lipopolysaccharide (LPS) Rifaximin Study

NCT02124512
Conditions
Obese, Insulin Resistance, Metabolic Syndrome
Interventions
Rifaximin SSD, Placebo
Drug · Other
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky